ESMO Open最新文献

{"title":"89P Duchenne muscular dystrophy gene product expression is associated with survival in sarcoma","authors":"S. Divakar , L. El-Khoury , K. Anthony , L.J. Machado","doi":"10.1016/j.esmoop.2025.104402","DOIUrl":"10.1016/j.esmoop.2025.104402","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 ","pages":"Article 104402"},"PeriodicalIF":7.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143679082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"84P Exploring BET inhibitors as promising agents for solitary fibrous tumor","authors":"J.L. Mondaza-Hernandez , Y. Li , P. Romero-Gonzalez , J. Lopez , J.T. Nguyen , D. Da Silva Moura , H.N. Hayenga , L. Bleris , J. Martin-Broto","doi":"10.1016/j.esmoop.2025.104397","DOIUrl":"10.1016/j.esmoop.2025.104397","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 ","pages":"Article 104397"},"PeriodicalIF":7.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143679248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"16P Survival outcomes and predictors in chromophobe renal cell carcinoma (ChRCC): A machine learning analysis","authors":"N. Almasri , S.A. Alshwayyat , T.A. Alshwayyat , M. Alshwayyat , J. Abu-Khass , A. Alenezy","doi":"10.1016/j.esmoop.2025.104324","DOIUrl":"10.1016/j.esmoop.2025.104324","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 ","pages":"Article 104324"},"PeriodicalIF":7.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143679352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"64MO Eribulin (E) versus trabectedin (T) therapy in patients with advanced liposarcoma: Efficacy comparison using real-world data evidence from TriNetX platform","authors":"J. Rodriguez Pascual , L. Ugidos , J.D. Rodriguez-Castaño , J.J. Serrano Domingo , G. Hernández-Ibarburu , M. Garcia Leirado , A. Ayuso","doi":"10.1016/j.esmoop.2025.104378","DOIUrl":"10.1016/j.esmoop.2025.104378","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 ","pages":"Article 104378"},"PeriodicalIF":7.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143680415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"72P Efficacy and safety of larotrectinib as first-line treatment for adult patients with TRK fusion cancer","authors":"M. Casanova , A. Drilon , R.S. McDermott , A. Italiano , M. Tahara , M.S. Brose , J.J. Lin , D-I. Burcoveanu , N. Neu , C.E. Mussi , L. Shen , D.S. Hong","doi":"10.1016/j.esmoop.2025.104386","DOIUrl":"10.1016/j.esmoop.2025.104386","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 ","pages":"Article 104386"},"PeriodicalIF":7.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143680910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"79P Pre-clinical study of tumor treating fields (TTFields) alone or in conjunction with systemic therapies in selected bone- and soft-tissue sarcomas","authors":"H.H.F. Loong, C.W.C. Hui, V.T.Y. Yeung, K.S.Y.K. Cheung, A. Tang, C-H. Wong","doi":"10.1016/j.esmoop.2025.104393","DOIUrl":"10.1016/j.esmoop.2025.104393","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 ","pages":"Article 104393"},"PeriodicalIF":7.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143681353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated clinico-molecular analysis of gastric cancer in European and Latin American populations: LEGACY project","authors":"R. Dienstmann ,&nbsp;E. Ruiz-García ,&nbsp;M. Alsina ,&nbsp;F. Ruiz-Pace ,&nbsp;T.S. Groen-van Schooten ,&nbsp;C. Martínez-Ciarpaglini ,&nbsp;E.A. Fernández-Figueroa ,&nbsp;R. Herrera-Goepfert ,&nbsp;C. Díaz-Romero ,&nbsp;L. Lino-Silva ,&nbsp;A.I. Hernandez-Guerrero ,&nbsp;N.M. Valdez-Reyes ,&nbsp;A. León-Takahashi ,&nbsp;J.C. Falcón-Martínez ,&nbsp;R.E. Pouw ,&nbsp;S. Romero ,&nbsp;R. Villagrasa ,&nbsp;M. Cabeza-Segura ,&nbsp;L. Alarcón-Molero ,&nbsp;E. Jimenez-Martí ,&nbsp;T. Fleitas","doi":"10.1016/j.esmoop.2025.104482","DOIUrl":"10.1016/j.esmoop.2025.104482","url":null,"abstract":"<div><h3>Background</h3><div>Gastric cancer (GC) is recognized for intrinsic heterogeneity, although it is similarly approached in Europe and Latin America (LATAM). The LEGACY project aimed to deepen GC molecular understanding through multi-omics analysis in Europe and LATAM GC samples.</div></div><div><h3>Patients and methods</h3><div>Tumor samples were centrally reviewed for histology, human epidermal growth factor receptor 2 (HER2) expression, and mismatch repair-deficient (dMMR)/microsatellite instability (MSI) status. In addition, we assessed Epstein–Barr virus (EBV) status, programmed death-ligand 1 (PD-L1) combined positive score (CPS), and carried out tissue genomic profiling including tumor mutation burden (TMB) quantification plus targeted transcriptomics for immune microenvironment and cancer cell signaling scores.</div></div><div><h3>Results</h3><div>In total, 328 GC patients were enrolled. HER2-positive GC and high PD-L1 CPS were more frequent in Europe than in LATAM (9% versus 3% and 15% versus 3%, respectively), whereas EBV was mainly found in LATAM (7%, versus 3% in Europe), and dMMR/MSI tumors were equally distributed (16%). High TMB was enriched in dMMR/MSI and EBV tumors. Mutations in homologous recombination repair (HRR) genes were frequent in both cohorts (24.8% and 14.7% in Europe and LATAM, respectively), and mostly found in dMMR/MSI (63.6%) and intestinal HER2-negative (18.7%) tumors. The prognosis was poor in diffuse HER2-negative GC patients, whose tumors presented an immunosuppressive microenvironment and other distinct pathway activation signatures.</div></div><div><h3>Conclusions</h3><div>Our findings relate specific molecular alterations of GC tumors from Europe and LATAM to actionable biomarkers for precision cancer therapies. The proposed GC stratification can be implemented in routine care and guide drug development strategies.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 3","pages":"Article 104482"},"PeriodicalIF":7.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143534907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"19P Body composition measures as a determinant of trastuzumab deruxtecan related toxicity and response","authors":"S. Strulov Shachar ,&nbsp;R. Kessner ,&nbsp;A. Sonnenblick ,&nbsp;Y. Bar ,&nbsp;S. Lerner ,&nbsp;A.T. Deutsch Lukatsky ,&nbsp;S. Yaacobi Peretz","doi":"10.1016/j.esmoop.2025.104175","DOIUrl":"10.1016/j.esmoop.2025.104175","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 ","pages":"Article 104175"},"PeriodicalIF":7.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143547919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"74P A phase I study for safety, tolerability, pharmacokinetics, and anti-tumor activity of ABM-1310 in patients (pts) with BRAF V600 mutation-positive solid tumors: The final result","authors":"J. Li ,&nbsp;Y. Sun ,&nbsp;J. Wen ,&nbsp;Y. Cheng ,&nbsp;Y. Fu ,&nbsp;Z. Yang ,&nbsp;C. Chen ,&nbsp;Z. Yang","doi":"10.1016/j.esmoop.2025.104233","DOIUrl":"10.1016/j.esmoop.2025.104233","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 ","pages":"Article 104233"},"PeriodicalIF":7.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"80P Real-world analysis of side effect profile of fibroblast growth factor receptor (FGFR) targeting agents and their correlation to clinical outcomes","authors":"A. Batra ,&nbsp;R. Singh ,&nbsp;A. Chitkara ,&nbsp;C.T. Jani ,&nbsp;J. Sharma","doi":"10.1016/j.esmoop.2025.104239","DOIUrl":"10.1016/j.esmoop.2025.104239","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"10 ","pages":"Article 104239"},"PeriodicalIF":7.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}